SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001628280-21-015865
Filing Date
2021-08-05
Accepted
2021-08-05 16:17:08
Documents
84
Period of Report
2021-06-30

Document Format Files

Seq Description Document Type Size
1 10-Q akba-20210630.htm   iXBRL 10-Q 2238895
2 EX-10.1 exhibit101-amendment1tosup.htm EX-10.1 22813
3 EX-31.1 exhibit311-q22021.htm EX-31.1 11366
4 EX-31.2 exhibit312-q22021.htm EX-31.2 11406
5 EX-32.1 exhibit321-q22021.htm EX-32.1 9276
  Complete submission text file 0001628280-21-015865.txt   9500358

Data Files

Seq Description Document Type Size
6 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT akba-20210630.xsd EX-101.SCH 85229
7 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT akba-20210630_cal.xml EX-101.CAL 98104
8 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT akba-20210630_def.xml EX-101.DEF 374928
9 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT akba-20210630_lab.xml EX-101.LAB 765812
10 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT akba-20210630_pre.xml EX-101.PRE 539470
11 EXTRACTED XBRL INSTANCE DOCUMENT akba-20210630_htm.xml XML 1464831
Mailing Address 245 FIRST STREET CAMBRIDGE MA 02142
Business Address 245 FIRST STREET CAMBRIDGE MA 02142 617-871-2098
Akebia Therapeutics, Inc. (Filer) CIK: 0001517022 (see all company filings)

IRS No.: 208756903 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-36352 | Film No.: 211148438
SIC: 2834 Pharmaceutical Preparations